Clearside Biomedical Bolsa (NASDAQ: CLSD)

Últimas noticias sobre Clearside Biomedical (NASDAQ:CLSD) Bolsa

Clearside Biomedical

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical Inc

Cryptocurrency markets are trading sideways despite key Bitcoin metrics rising.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$61,248</td>
<td>-1.2%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,412</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$140.6</td>
<td>-1.5%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1087</td>
<td>+1.98%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001697</td>
<td>-0.9%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 5.6% and daily active addresses growing by 16.5%. Transactions greater than $100,000 are up from 8,143 to 9,459 in a single day. Exchanges netflows are up by 222%.</li>
<li>Coinglass data reports 47,550 traders were liquidated in the past 24 hours, with total liquidations at $102.54 million. Crypto short liquidations stand at $23.5 million, the lowest since Sep. 15.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41252337/bitget-predicts-solana-to-hit-up-to-180-in-october-meme-coin-boom-to-continue">Bitget Predicts Solana To Hit Up To $180 In October, Meme Coin Boom To Continue</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41251603/vaneck-launches-30m-early-stage-fund-for-digital-assets-ai-startups">VanEck Launches $30M Early-Stage Fund For Digital Assets, AI Startups</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41250621/peter-todd-says-im-not-satoshi-but-not-everyones-buying-that-just-as-plausible-as-the-othe">Peter Todd Says &#8216;I&#8217;m Not Satoshi&#8217; But Not Everyone&#8217;s Buying That: &#8216;Just As Plausible&#8217; As The Other Theories, Says Financial Journalist</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41247885/maxine-waters-fuels-optimism-for-stablecoin-legislation-deal-with-chairman-mchenry-before-">Maxine Waters Fuels Optimism For Stablecoin Legislation Deal With Chairman McHenry Before 2024 Ends</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41252584/caroline-ellison-settles-ftx-lawsuit-agrees-to-forfeit-majority-of-assets">Caroline Ellison Settles FTX Lawsuit, Agrees To Forfeit Majority Of Assets</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Chiliz (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/chz/usd">CHZ</a>)</td>
<td>&nbsp;$0.07538</td>
<td>+14.96%</td>
</tr>
<tr>
<td>Helium (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hnt/usd">HNT</a>)</td>
<td>&nbsp;$6.80</td>
<td>+2.5%</td>
</tr>
<tr>
<td>First Neiro On Ethereum (CRYPTO: NEIRO)</td>
<td>&nbsp;$0.001768</td>
<td>+2.2%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices trading down, crypto trader Justin Bennett <a href="https://x.com/JustinBennettFX/status/1844069519699886563">stated</a> that it would be typical for Bitcoin to run both sides and then continue sideways when everyone is expecting $70,000.
Crypto trader Degen Hardy charted out Bitcoin's behaviour after every U.S. election.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> behavior after every US elections! Patience fam, PUMP is soon! <a href="https://t.co/1RkEkZDFzz">pic.twitter.com/1RkEkZDFzz</a>
&mdash; Hardy (@Degen_Hardy) <a href="https://twitter.com/Degen_Hardy/status/1844014963205214475?ref_src=twsrc%5Etfw">October 9, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another trader, CryptosBatman, drew parallels between Bitcoin's current and October 2023 performance. He marked that this was where it formed a local top in the first week before rallying. While he sees the same setup currently, he is concerned about the recent weak candles. He <a href="https://x.com/CryptosBatman/status/1844068896032293124">concluded</a>, "Let's hope BTC holds its current level and pushes higher in the coming weeks."
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41256610/the-best-way-to-trade-bitcoin-after-the-fomc-minutes">The Best Way To Trade Bitcoin After The FOMC Minutes</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$CHZ

$DOGE

$ETH

$HNT

$SHIB

$SOL

Bitcoin, Ethereum, Dogecoin Trade Sideways, Trader Predicts Rally Soon But Worried About 'Recent Weak Candles'

Citigroup analyst James Hardiman maintains Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Buy and raises the price target from $204 to $253.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Royal Caribbean Gr, Raises Price Target to $253

WIIM

RBLX

Roblox shares are trading higher after Wells Fargo raised its price target from $46 to $54.

Fidelity National Info's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) short percent of float has risen 5.96% since its last report. The company recently reported that it has 12.59 million shares sold short, which is 3.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Fidelity National Info Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728501324_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fidelity National Info has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Fidelity National Info's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Fidelity National Info's peer group average for short interest as a percentage of float is 5.77%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Fidelity National Info?

JetBlue Airways's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NYSE">JBLU</a>) short percent of float has fallen 9.42% since its last report. The company recently reported that it has 62.58 million shares sold short, which is 25.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.59 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>JetBlue Airways Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728501318_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for JetBlue Airways has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing JetBlue Airways's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, JetBlue Airways's peer group average for short interest as a percentage of float is 10.89%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

JBLU

How Is The Market Feeling About JetBlue Airways?

BJ's Wholesale Club's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) short percent of float has fallen 3.01% since its last report. The company recently reported that it has 7.58 million shares sold short, which is 7.4% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>BJ's Wholesale Club Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728501313_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for BJ's Wholesale Club has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing BJ's Wholesale Club's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, BJ's Wholesale Club's peer group average for short interest as a percentage of float is 3.44%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(BJ) - Analyzing BJ's Wholesale Club's Short Interest

Investors looking to enter PepsiCo (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pep#NASDAQ">PEP</a>) stock or build on existing positions should rejoice. The FQ3 2024 earnings report was weaker than expected, causing the stock price to dip. While weaker-than-expected results and a soft outlook for revenue aren&#39;t news to be happy about, the tally isn&#39;t as bad as headlines make it seem, and there is the long-term outlook to consider.&nbsp;
PepsiCo is the world&#39;s largest consumer staples company, impacted by internal and external one-offs that will soon pass. Until then, it is a solid, reliable dividend payer of Dividend King quality and will weather the current downturn in activity as it has done in the past, which is very well.
The critical details for investors to focus on today are the valuation and dividend yield. The stock, down from highs set in 2023, trades at roughly 20.5x its earnings outlook at the low end of the historical range. Likewise, the dividend distribution, which is expected to continue growing, yields about 3.25%, with shares near critical support levels and at the high end of the historical range. Investors that buy in at the current levels have limited risk and potential for a 50% share price increase at the high-end valuation range. There can be no better time to enter a blue chip stock such as this regarding long-term investing, portfolio maximization, total returns, and dollar-cost averaging.
<h2>PepsiCo&#39;s Soft Q3 Is No Concern for Long-Term Investors</h2>
PepsiCo had a softer-than-expected Q3, but each negative was offset by a positive, leaving shareholder value improved and the long-term outlook unchanged. The $23.32 billion in net revenue is down -0.6% compared to last year and missed the consensus by 200 bps, but organic growth is present, and the margin is good. Organically, core operations are up 1.3%.&nbsp;
Segmentally, Quaker North America was the weakest, with a contraction of 13%. However, the weakness is primarily due to the recalls in Q1 and the subsequent shuttering of a plant believed to be the source of contamination. Weakness was also seen in Frito Lay North America, but the 1% contraction is less of a concern and offset by organic growth in PepsiCo North America, Latin America, and Europe. Asia-Pacific (APAC) is the weakest regionally, with a contraction of -1%, impacted by rising geopolitical tensions.
PepsiCo experienced margin contraction in Q3, but aggressive cost controls and increased efficiencies produced a better-than-expected result.&nbsp; The takeaway is that adjusted earnings grew compared to last year and outpaced the consensus target and organic revenue growth. Because cost controls and investment in operational efficiencies are part of the equation, investors can expect a leverage rebound in earnings when top-line growth resumes, likely to be sometime in F2025.&nbsp;
Guidance is also mixed, with the revenue target reduced but organic EPS growth targets reaffirmed. The salient detail is that operational improvements are expected to stick, providing sufficient cash flow to sustain the fortress balance sheet while returning capital to investors and investing in the business. Regarding the balance sheet, the company produced positive cash flow operationally but negative cash flow for the business. However, that detail is offset by the timing of debt issuance and repayment, increased assets, decreased liability, and a 5% improvement in shareholder equity.&nbsp;
<h2>PepsiCo Capital Returns Help Support the Price Action over Time</h2>
PepsiCo&#39;s capital return is reliably safe and growing. The company&#39;s dividend distribution is up 7% per share compared to 2023, aided by repurchases. The repurchase activity is up incrementally compared to last year, and the count was reduced by 0.35% for the quarter and YTD periods. Investors may expect to see distribution increases slow in 2025 but not cease; share repurchases are also likely to continue at the current pace.&nbsp;
The price action in PepsiCo stock was tepid following the release, leaving the stock price down in early trading. However, the market is trading near a floor at $160, where support has been strong and is likely to produce a rebound. The $160 floor coincides with a significant uptrend line in 2024, so the rebound could be strong and result in a sustained uptrend in 2024.&nbsp;
Among the catalysts for 2025 are a return to top-line growth, leveraged results on the bottom line, and the possibility that growth will exceed the current forecasts because of the addition of Siete Foods. Siete Foods is a Mexican-American food brand growing above the industry&#39;s 4% CAGR, providing inroads into a new product vertical worth billions in annual revenue while complementing PepsiCo&#39;s better-for-you food offerings.&nbsp;
<img alt="PepsiCo PEP stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241008081101_chart-pep-1082024.png" style="height:423px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/this-is-the-entry-into-pepsico-youve-been-waiting-for/">This Is the Entry Into PepsiCo You&#39;ve Been Waiting For</a>&quot; first appeared on MarketBeat.

Earnings

Large Cap

Guidance

Dividends

Technicals

Offerings

Contracts

Markets

This Is the Entry Into PepsiCo You've Been Waiting For

NetEase Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) shares are trading lower by 5.28% to $89.45 Wednesday afternoon. Shares of U.S.-listed Chinese stocks are trading lower on continued weakness after Chinese planning officials reportedly fell short of <a href="https://www.benzinga.com/news/24/10/41254085/china-stock-rally-loses-steam-as-investor-optimism-subsides-not-quite-enough-to-satiate-lofty-expect">investor stimulus expectations</a>.
What To Know: As concerns mount over China's slowing economy, NetEase, which relies heavily on consumer spending on gaming and digital services, is facing increased uncertainty about its growth prospects.
NetEase, known for its popular online games like Fantasy Westward Journey and Justice, as well as its expanding music and education platforms, is deeply tied to the health of China's consumer market. 
The company's stock took a hit as investors reacted to underwhelming announcements from China's National Development and Reform Commission (NDRC), which failed to deliver the large-scale economic stimulus many had been hoping for. 
While expectations were high for new measures to boost consumption and stimulate growth, the NDRC's announcements were limited to modest infrastructure spending and future projects, far short of the significant fiscal support that could have shored up consumer confidence.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/10/41254642/s-p-500-hits-new-all-time-high-ahead-of-fed-minutes-as-lower-oil-prices-offer-relief-whats-driving-">S&amp;P 500 Hits New All-Time High Ahead Of Fed Minutes As Lower Oil Prices Offer Relief: What&#8217;s Driving Markets Wednesday?</a>
This lack of aggressive stimulus has raised concerns about weaker consumer spending, particularly in discretionary sectors like gaming and entertainment, which are critical to NetEase's business. With China's economy facing headwinds from slowing growth and a shaky property market, there are fears that consumers may cut back on non-essential spending, including gaming, digital services, and in-app purchases. 
For a company like NetEase, which generates significant revenue from its gaming division, any slowdown in consumer spending could impact its top line.
What Else: NetEase's reliance on a robust domestic consumer base for its gaming revenue makes it particularly vulnerable to shifts in China's economic environment. 
If consumers become more cautious with spending, demand for entertainment products like video games and digital content could slow, putting pressure on NetEase's growth.
Despite the current challenges, NetEase has been investing heavily in expanding its portfolio of games and services, including international expansion through its gaming division, which has produced hit titles globally. The company has also been diversifying into new areas like cloud music services and online education, which have shown growth potential.
However, the lack of strong consumer stimulus from Beijing may weigh on these efforts in the near term, as economic uncertainty dampens consumer willingness to spend on digital entertainment.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41257938/fed-minutes-reveal-heated-debate-over-september-interest-rate-move-traders-trim-november-easing-">Fed Minutes Reveal Heated Debate Over September Interest Rate Move: Traders Trim November Easing Bets</a>
<h2 class="wp-block-heading">How To Buy NTES Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in NetEase&#8217;s case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NTES has a 52-week high of $118.89 and a 52-week low of $75.85.

NTES

Why NetEase (NTES) Stock Is Down 5% Today

Everest Group shares are trading higher after Jefferies maintained a Buy rating on the stock and raised its price target from $440 to $457.

Landstar System (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lstr#NASDAQ">LSTR</a>) is benefiting from its robust financial stability and strong liquidity. The shareholder-friendly approach also bodes well for the company. However, the company is grappling with the freight market downturn.
<h2>Factors Favoring LSTR</h2>
Landstar&#39;s commitment to shareholder value is commendable, as the company consistently returns significant capital to its investors through stock repurchase programs and dividends. In the first half of 2024, Landstar repurchased shares of its common stock for a total of $57 million and paid $95 million in dividends. Moreover, in August 2024, LSTR paid a quarterly dividend of $0.36 per share to its stockholders. This quarterly dividend includes a 9% increase to its regular quarterly dividend.
Despite the softness prevailing in the freight environment, the company demonstrates strong financial stability and cash-generating capabilities. By the end of the second quarter of 2024, LSTR reported cash and short-term investments totaling $504 million. For the first half of 2024, cash flow from operations reached $142 million, while cash capital expenditures amounted to $17 million.
The company exited the second quarter of&nbsp;2024 with a current ratio (a&nbsp;measure of liquidity) of 2.17. A current ratio of greater than 1 is always desirable as it indicates that the company has enough cash to meet its short-term obligations.
Shares of LSTR have rallied 4.3% over the past year compared to the&nbsp;industry&#39;s decline of 4.9% in the same period.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/2f/80936.jpg?v=1698351877" />
Image Source: Zacks Investment Research
<h2>LSTR: Key Risks to Watch </h2>
The company&#39;s prospects are being negatively affected by softness in freight market demand. In the second quarter of 2024, total loadings of machinery dropped by 12% year over year. Similarly, loadings for automotive equipment and parts fell by 1%, while building products and hazardous materials decreased by 1% and 14%, respectively.
Moreover, substitute linehaul loadings, which had been one of the strongest performers during the pandemic and are highly sensitive to consumer demand, decreased by 29% compared to the second quarter of 2023.
As a result, Landstar&#39;s top line is expected to remain weak in the near term. For the third quarter of 2024, the company anticipates a decline in truckloads in the range of 6-10% year over year.
The trucking industry is also grappling with a persistent driver shortage. As seasoned drivers retire, companies struggle to attract new talent, particularly from younger generations, who may not find the profession appealing.
<h2>LSTR&#39;s Zacks Rank</h2>
LSTR currently carries a Zacks Rank #3 (Hold).
<h2>Stocks to Consider</h2>
Some better-ranked stocks for investors&#39; consideration in the Zacks Transportation sector include Ryanair (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ryaay#NASDAQ">RYAAY</a>) and Canadian Pacific Kansas City Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cp#NYSE">CP</a>).
Ryanair currently sports a Zacks Rank #1 (Strong Buy).&nbsp;RYAAY has an expected earnings growth rate of 10% for the current year.
The company has a discouraging earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, delivering an average miss of 30%. Shares of RYAAY have risen 10.2% in the past year.
Canadian Pacific also sports a Zacks Rank #1 at present and has an expected earnings growth rate of 0.3% for the current year.
The company has an encouraging track record with respect to the earnings surprise, having surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missing once. The average beat is 2.2%. CP shares have rallied 10.6% in the past year.
<a href="https://www.zacks.com/stock/news/2348380/here-s-why-investors-should-hold-on-to-landstar-stock-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2348380">To read this article on Zacks.com click here.</a>

Earnings Misses

Mid Cap

LSTR

RYAAY

Here's Why Investors Should Hold on to Landstar Stock Now

<a href="https://www.federalreserve.gov/monetarypolicy/fomcminutes20240731.htm" title="https://www.federalreserve.gov/monetarypolicy/fomcminutes20240731.htm">https://www.federalreserve.gov/monetarypolicy/fomcminutes20240731.htm</a>

Macro Economic Events

Econ #s

Economics

Minutes of the Federal Open Market Committee September 17–18, 2024 (Link In Body)

The market capitalization of meme coins is trading sideways over the last 24 hours, with a majority of established memes like Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>), Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) and Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) failing to back up <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41207040/dogecoin-killer-shiba-inu-up-39-over-the-past-30-days-but-that-will-accelerate-says-bullis">their September gains.</a>
What Happened: Crypto trader Unipcs highlighted that despite the hype around newer coins, established ones like Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), Shiba Inu, Floki (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOKI</a>), Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>), Dogwifha, and Pepe are <a href="https://x.com/theunipcs/status/1843679786784129184">poised</a> for a significant rally.
Unipcs referenced the previous cycle where SHIB unexpectedly surged 10x in weeks, surpassing DOGE in market capitalization. He suggested that the same could happen now, with established meme coins outperforming the new ones.
 "Your shiny new meme coins will take a breather soon, then the established meme coins will pull a super aggressive monster rally that will make you gasp for breathe," the trader noted.
He emphasized that established meme coins are traded on the most liquid outlets and have enough liquidity to absorb massive buy and sell volumes from big funds.
Unipcs also pointed out that both retail and institutional investors trust established meme coins due to their stability and resistance to market manipulations.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41097318/meme-coin-supercycle-means-13-out-of-top-20-outperforming-tokens-are-memes-will-shiba-doge">&#8216;Meme Coin Supercycle&#8217; Means 13 Out Of Top 20 Outperforming Tokens Are Memes: Will Shiba, Dogecoin Be First To Reach $100B?</a>
Meme coin leaders Dogecoin and Shiba Inu have clocked 6.6% and 26.4% gains over the past 30 days but are trading mostly sideways or down since the start of October.
Shiba Inu has seen consistent <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41163167/dogecoin-killer-shiba-inus-burn-rate-increases-227-then-why-are-technical-indicators-so-we">token burns</a> but has failed to make up further ground over the past week.
What's Next: Meme coins will be one of the central topics at the upcoming Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41044014/dogecoin-up-6-shiba-inu-surges-14-whats-going-on-with-the-meme-coin-kings">Dogecoin Up 6%, Shiba Inu Surges 14%: What&#8217;s Going On With The Meme Coin Kings?</a></li>
</ul>
Image: Shutterstock

$BONK

$FLOKI

$PEPE

$WIF

Dogecoin, Shiba Inu, Dogwifhat Struggle But 'Established Meme Coins Will Pull A Super Aggressive Monster Rally,' Trader Vows

Finding a balance between getting more scale, but still being productive and having high margins in the current landscape in the cannabis industry, is a "daily challenge." That's according to Charlie Bachtell, CEO and co-founder of Cresco Labs Inc (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTCQX">CRLBF</a>), a company running over 70 cannabis retail locations nationwide.
It involves continually adapting to new challenges, strategies, and emerging trends across a company's operations. "You&#8217;re constantly trying to forecast where this industry is headed and at the same time, understand the industry that you&#8217;re in today," Bachtell said during a fireside chat with Jesse Redmond, head of cannabis at Water Tower Research LLC, at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> on Wednesday, in Chicago.
He added that running a cannabis business over the past decade depended heavily on how well organizations have been able to speculate about how fast and in what direction the nascent market would go.
The cannabis industry is unique among other "super fast-moving" emerging industries due to challenges to access capital and the impact of 280e on taxation.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09132606/ccc-oct-24-banner__1_-20.gif" alt="" class="wp-image-588186" /></a></figure>
"Not only are you fighting this fight with one and a half hands tied behind your back, but then you are also expected to get profitable too," Bachtell said, adding it&#8217;s a constant evaluation and balancing growth while maintaining margins.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41250811/exclusive-were-finally-on-the-cusp-of-something-big-verano-ceo-sees-cannabis-rescheduling-as-gam">EXCLUSIVE: &#8216;We&#8217;re Finally On The Cusp Of Something Big&#8217; — Verano CEO Sees Cannabis Rescheduling As Game-Changer</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">A Success Story</h3>
Cresco Labs made its debut in Chicago in 2013 when Illinois passed the Compassionate Use of Medical Cannabis Act. &#8220;The company's goal and that of its management team has been to help normalize and professionalize this industry,&#8221; Bachtell said.
Following nascent years of getting the first buildings built and becoming operational, the company has been scaling ever since. After attempting and failing to merge with Columbia Care Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CCHWF#OTC">CCHWF</a>) &#8211; now known as The Cannabist Company Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBSTF#OTC">CBSTF</a>) &#8211; 2023 came as "the year of the core."
"After attempting the large MMA deal, we really needed to focus on our core business and making sure that we got Cresco Labs as tight and as sound and as efficient as we possibly could, which would then best prepare us for growth in the years ahead," he said.
Year-to-date, Cresco has positioned itself to capitalize on catalysts, such as potential shifts to recreational markets in states where it already operates as a medical cannabis provider, including Ohio, Florida, and Pennsylvania, where the regulatory landscape continues to evolve.
It is important to figure out "ways to get smarter… leaner and get more juice from the same squeeze," Bachtell said. The primary focus should be to develop "skill sets that are transportable and transferable from state to state in the limited ability that you have to do it."
<h3 class="wp-block-heading">Seizing Cannabis Regulatory Shifts</h3>
That said, Bachtell is optimistic Florida's <a href="https://www.benzinga.com/markets/cannabis/24/10/41250277/miami-herald-endorses-florida-cannabis-legalization-highlights-failed-drug-war-revenue-potential">Amendment 3</a> would allow the company to go recreational in the state. Former President Donald Trump&#8216;s support has increased the likelihood of the success, he added.
"The two leaders of the main political parties in the United States both being in favor of legalization is something that we should not miss, and recognize the importance of it," Bachtell said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41241003/exclusive-cannabis-rescheduling-is-not-cure-all-for-industry-problems-experts-explain-how-tax-ta">EXCLUSIVE: Cannabis Rescheduling Is Not Cure-All For Industry Problems: Experts Explain How Tax Tactics Could Hurt Marijuana Businesses In Long Run</a></li>
</ul>
Charlie Bachtell, CEO and co-founder of Cresco Labs, speaks at the Benzinga Cannabis Capital Conference on Wednesday. Photo by Wendy Davis.

Cannabis

Entrepreneurship

Events

Exclusives

Interview

THE CANNABIST CO HLDG by THE CANNABIST COMPANY HOLDINGS INC.

CBSTF

CCHWF

CRLBF

EXCLUSIVE: Cannabis Companies Must 'Get More Juice From The Same Squeeze,' Says Cresco Labs CEO As Challenges Persist

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Amphenol, revealing an average target of $70.4, a high estimate of $76.00, and a low estimate of $65.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.35%. 
<img src="https://www.benzinga.com/files/images/story/2024/1728500545_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Amphenol's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Wamsi Mohan</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$74.50</td>
</tr>
<tr>
<td>Luke Junk</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Kevin McCarthy</td>
<td>Vertical Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$65.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Amphenol. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Amphenol compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Amphenol's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Amphenol's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/APH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amphenol analyst ratings.</a>
<h2>All You Need to Know About Amphenol</h2>
Amphenol is a global supplier of connectors, sensors, and interconnect systems. Amphenol holds the second-largest connector market share globally and sells into the end markets of automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks. Amphenol is diversified geographically, with operations in 40 countries.
<h3>Key Indicators: Amphenol's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Amphenol's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.2% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Amphenol's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.54% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amphenol's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.94%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.97%, the company showcases effective utilization of assets.
Debt Management: Amphenol's debt-to-equity ratio surpasses industry norms, standing at 0.61. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 5 Analyst Projections For Amphenol

Hedera's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>) price has decreased 3.25% over the past 24 hours to $0.05, continuing its downward trend over the past week of -1.0%, moving from $0.05 to its current price. 
The chart below compares the price movement and volatility for Hedera over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1728500544_0.png" alt="price_chart" />
The trading volume for the coin has fallen 31.0% over the past week which is opposite, directionally, with the overall circulating supply of the coin, which has increased 0.09%. This brings the circulating supply to 37.65 billion, which makes up an estimated 75.31% of its max supply of 50.00 billion. According to our data, the current market cap ranking for HBAR is #50 at $1.90 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1728500544_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

$HBAR

Cryptocurrency Hedera Decreases More Than 3% Within 24 hours

4 analysts have shared their evaluations of Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $20.25, along with a high estimate of $27.00 and a low estimate of $10.00. A decline of 1.22% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1728500522_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Enanta Pharma is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Enanta Pharma. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Enanta Pharma compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Enanta Pharma's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Enanta Pharma's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ENTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enanta Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Enanta Pharma: A Closer Look</h2>
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
<h3>A Deep Dive into Enanta Pharma's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Enanta Pharma faced challenges, resulting in a decline of approximately -4.88% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Enanta Pharma's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -126.08%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Enanta Pharma's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -14.38%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Enanta Pharma's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.58%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTA

A Glimpse Into The Expert Outlook On Enanta Pharma Through 4 Analysts

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $61.0, a high estimate of $65.00, and a low estimate of $59.00. This upward trend is evident, with the current average reflecting a 3.39% increase from the previous average price target of $59.00.
<img src="https://www.benzinga.com/files/images/story/2024/1728500514_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Delta Air Lines is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$59.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>David Vernon</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Sheila Kahyaoglu</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Helane Becker</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$59.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>David Vernon</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$66.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Delta Air Lines. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Delta Air Lines compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Delta Air Lines's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Delta Air Lines's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DAL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Delta Air Lines analyst ratings.</a>
<h2>Delving into Delta Air Lines's Background</h2>
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned the greatest portion of its international revenue and profits from flying passengers over the Atlantic Ocean.
<h3>Delta Air Lines: A Financial Overview</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Delta Air Lines's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.93%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Delta Air Lines's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.83% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Delta Air Lines's ROE excels beyond industry benchmarks, reaching 11.09%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.74%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 2.0.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 5 Ratings For Delta Air Lines

Throughout the last three months, 9 analysts have evaluated Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $26.44, a high estimate of $43.00, and a low estimate of $8.00. This upward trend is apparent, with the current average reflecting a 21.4% increase from the previous average price target of $21.78.
<img src="https://www.benzinga.com/files/images/story/2024/1728500500_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Capricor Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jason McCarthy</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason McCarthy</td>
<td>Maxim Group</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Capricor Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Capricor Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Capricor Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Capricor Therapeutics</h2>
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
<h3>Financial Milestones: Capricor Therapeutics's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Capricor Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.38% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -276.97%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Capricor Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -73.49%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Capricor Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -25.08%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.16.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAPR

Forecasting The Future: 9 Analyst Projections For Capricor Therapeutics

In the preceding three months, 4 analysts have released ratings for Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $86.75, a high estimate of $95.00, and a low estimate of $74.00. Surpassing the previous average price target of $78.00, the current average has increased by 11.22%.
<img src="https://www.benzinga.com/files/images/story/2024/1728500486_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Axis Capital Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$74.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Harry Fong</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Axis Capital Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axis Capital Holdings compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Axis Capital Holdings's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Axis Capital Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AXS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Axis Capital Holdings analyst ratings.</a>
<h2>All You Need to Know About Axis Capital Holdings</h2>
Axis Capital Holdings Ltd is a property and casualty insurance company that provides various products and services to clients and distribution partners. The company has operating subsidiaries and branch networks based in Bermuda, the United States, Canada, Europe, and Singapore. Its business consists of two distinct global underwriting platforms, AXIS Insurance, and AXIS Reinsurance. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks.
<h3>A Deep Dive into Axis Capital Holdings's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Axis Capital Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.69% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Axis Capital Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.9% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.06%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Axis Capital Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.64%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.3.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Axis Capital Holdings Stock

Over the past 24 hours, Optimism's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">OP</a>) price has fallen 4.21% to $1.55. This continues its negative trend over the past week where it has experienced a 0.0% loss, moving from $1.6 to its current price. 
The chart below compares the price movement and volatility for Optimism over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1728500475_0.png" alt="price_chart" />
The trading volume for the coin has tumbled 32.0% over the past week along with the circulating supply of the coin, which has fallen 0.09%. This brings the circulating supply to 1.26 billion, which makes up an estimated 29.22% of its max supply of 4.29 billion. According to our data, the current market cap ranking for OP is #48 at $1.94 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1728500475_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cryptocurrency Optimism Falls More Than 4% In 24 hours

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Clearside Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/clsd-stock-quote/">CLSD</a>) just reported results for the second quarter of 2024.<ul><li>Clearside Biomedical reported earnings per share of -10 cents. This was above the analyst estimate for EPS of -13 cents.</li><li>The company reported revenue of $90,000.</li><li>This was 40% worse than the analyst estimate for revenue of $150,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/clsd-stock-earnings-clearside-biomedical-for-q2-of-2024/">CLSD Stock Earnings: Clearside Biomedical Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CLSD Stock Earnings: Clearside Biomedical Beats EPS, Misses Revenue for Q2 2024

Clearside Biomedical (CLSD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Wolleb...

Buy Rating Affirmed for Clearside Biomedical Ahead of ODYSSEY Trial Results

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Clearside Biomedical (CLSD – Research Report) today and set a price target of $5.0...

Oppenheimer Sticks to Its Buy Rating for Clearside Biomedical (CLSD)

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on CLSD stock, giving a Buy rating on August 21. Debanjana Chatterjee...

Optimistic Buy Rating for Clearside Biomedical Amid Promising ODYSSEY Trial Results and Strong Financial Position

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report), with a ...

Clearside Biomedical: A Strong Buy on Promising ODYSSEY Trial Outcomes and Market Re-Rating Potential

Clearside Biomedical (CLSD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H....

Clearside Biomedical's CLS-AX Shows Promise in Phase 2b Trials, Yi Chen Maintains Buy Rating with $5 Price Target

In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report), with a...

Buy Rating for Clearside Biomedical's CLS-AX Based on Superior Efficacy and Market Adoption Potential

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on aTyr Pharma (ATYR – Research Report) and Clearside B...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Clearside Biomedical (CLSD – Research Report). The associated price...

Buy Rating on Clearside Biomedical: Promising ODYSSEY Trial Results and Undervalued Market Position

Needham analyst Serge Belanger has maintained their bullish stance on CLSD stock, giving a Buy rating today. Serge Belanger has given his Buy ratin...

Buy Rating Affirmed with Increased Price Target for Clearside Biomedical Post-ODYSSEY Trial Success

ATYR

CLSD

Press Releases

Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

General

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

Health Care

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Comments

Clearside Biomedical

Noticias

Últimas noticias sobre Clearside Biomedical (NASDAQ:CLSD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL